CN101043888B - 制备异噻唑衍生物的方法 - Google Patents

制备异噻唑衍生物的方法 Download PDF

Info

Publication number
CN101043888B
CN101043888B CN2005800284337A CN200580028433A CN101043888B CN 101043888 B CN101043888 B CN 101043888B CN 2005800284337 A CN2005800284337 A CN 2005800284337A CN 200580028433 A CN200580028433 A CN 200580028433A CN 101043888 B CN101043888 B CN 101043888B
Authority
CN
China
Prior art keywords
formula
isothiazole
chemical compound
methyl
benzyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800284337A
Other languages
English (en)
Chinese (zh)
Other versions
CN101043888A (zh
Inventor
大卫·B·达蒙
布赖恩·P·琼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
OSI Pharmaceuticals LLC
Original Assignee
Pfizer Ltd Great Britain
Pfizer Products Inc
OSI Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd Great Britain, Pfizer Products Inc, OSI Pharmaceuticals LLC filed Critical Pfizer Ltd Great Britain
Publication of CN101043888A publication Critical patent/CN101043888A/zh
Application granted granted Critical
Publication of CN101043888B publication Critical patent/CN101043888B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN2005800284337A 2004-08-26 2005-08-02 制备异噻唑衍生物的方法 Expired - Fee Related CN101043888B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60454204P 2004-08-26 2004-08-26
US60/604,542 2004-08-26
PCT/US2005/027398 WO2006026034A2 (en) 2004-08-26 2005-08-02 Processes for the preparation of isothiazole derivatives

Publications (2)

Publication Number Publication Date
CN101043888A CN101043888A (zh) 2007-09-26
CN101043888B true CN101043888B (zh) 2010-08-11

Family

ID=36000502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800284337A Expired - Fee Related CN101043888B (zh) 2004-08-26 2005-08-02 制备异噻唑衍生物的方法

Country Status (21)

Country Link
US (2) US8884025B2 (enExample)
EP (1) EP1784183B1 (enExample)
JP (2) JP5100390B2 (enExample)
KR (1) KR100893977B1 (enExample)
CN (1) CN101043888B (enExample)
AR (1) AR050613A1 (enExample)
AT (1) ATE542533T1 (enExample)
AU (1) AU2005280451B2 (enExample)
BR (1) BRPI0514667A (enExample)
CA (1) CA2578023C (enExample)
DK (1) DK1784183T3 (enExample)
ES (1) ES2378994T3 (enExample)
IL (1) IL181063A0 (enExample)
MX (1) MX2007002246A (enExample)
NO (1) NO20071319L (enExample)
PL (1) PL1784183T3 (enExample)
PT (1) PT1784183E (enExample)
RU (1) RU2349588C2 (enExample)
TW (1) TWI361688B (enExample)
WO (1) WO2006026034A2 (enExample)
ZA (1) ZA200701016B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002246A (es) 2004-08-26 2007-04-20 Pfizer Prod Inc Procedimientos para la preparacion de derivados de isotiazol.
ES2623652T3 (es) 2011-12-28 2017-07-11 Allergan, Inc. Derivados de 3-fenil-5-ureidoisotiazol-4-carboximida y 3-amino-5-fenilisotiazol como inhibidores de cinasa
CN103833665B (zh) * 2014-02-24 2015-09-23 杰达维（上海）医药科技发展有限公司 一种新的合成异噻唑的方法
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
KR20250121146A (ko) * 2022-12-28 2025-08-11 비양 테라퓨틱스 컴퍼니 리미티드 단백질 티로신 키나제 억제제 및 이의 의약적 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235764B1 (en) * 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
IL72093A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
JP4511352B2 (ja) * 2002-07-25 2010-07-28 ファイザー・インク 抗癌薬として有用なイソチアゾール誘導体
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
MX2007002246A (es) 2004-08-26 2007-04-20 Pfizer Prod Inc Procedimientos para la preparacion de derivados de isotiazol.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235764B1 (en) * 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents
US6548526B2 (en) * 1998-06-04 2003-04-15 Pfizer Inc Isothiazole derivatives useful as anticancer agents

Also Published As

Publication number Publication date
AU2005280451A1 (en) 2006-03-09
CA2578023C (en) 2012-05-15
US20150065726A1 (en) 2015-03-05
PT1784183E (pt) 2012-03-09
BRPI0514667A (pt) 2008-06-17
JP5100390B2 (ja) 2012-12-19
ZA200701016B (en) 2008-05-28
EP1784183A2 (en) 2007-05-16
AR050613A1 (es) 2006-11-08
RU2007106847A (ru) 2008-08-27
JP5498524B2 (ja) 2014-05-21
WO2006026034A3 (en) 2006-06-29
MX2007002246A (es) 2007-04-20
RU2349588C2 (ru) 2009-03-20
CN101043888A (zh) 2007-09-26
NO20071319L (no) 2007-05-29
IL181063A0 (en) 2007-07-04
AU2005280451B2 (en) 2009-02-05
PL1784183T3 (pl) 2012-07-31
KR100893977B1 (ko) 2009-04-20
US20090023924A1 (en) 2009-01-22
TWI361688B (en) 2012-04-11
DK1784183T3 (da) 2012-04-02
US9371298B2 (en) 2016-06-21
KR20070070158A (ko) 2007-07-03
HK1111359A1 (en) 2008-08-08
JP2008510841A (ja) 2008-04-10
EP1784183A4 (en) 2009-12-09
ES2378994T3 (es) 2012-04-19
CA2578023A1 (en) 2006-03-09
US8884025B2 (en) 2014-11-11
WO2006026034A2 (en) 2006-03-09
JP2012153705A (ja) 2012-08-16
TW200621241A (en) 2006-07-01
ATE542533T1 (de) 2012-02-15
EP1784183B1 (en) 2012-01-25

Similar Documents

Publication Publication Date Title
KR100392434B1 (ko) 항암제로 유용한 이소티아졸 유도체
TWI314928B (en) 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US9604980B2 (en) Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
US9371298B2 (en) Processes for the preparation of isothiazole derivatives
JP5165748B2 (ja) イミダゾリジノン誘導体
DE69519666T2 (de) Durch einen pyridinring substituierte thiazolidine und oxazolidine und ihre anwendung als hypoglykämische mittel
AU2005247855A1 (en) Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders
AU2004291147A1 (en) Urea derivatives as kinase modulators
BRPI0912878A2 (pt) derivados de indazóis substituídos por fenila e benzodioxinila
CN108191861B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺
CN115551846A (zh) 1,4,5,6-四氢嘧啶-2-胺衍生物
CN108383828A (zh) 作为趋化因子受体调节剂的新的1，2-双-磺酰胺衍生物
HK1111359B (en) Processes for the preparation of isothiazole derivatives
CN120842215A (zh) 一类线型的泛kras抑制剂及其制备方法与应用
CN113773273A (zh) 苯并异噻唑类化合物及其制备方法和用途
AU2013201455A8 (en) Benzoheterocyclic compounds and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1111359

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: PFIZER(WARNER-LAMBERT) CO., LTD.

Free format text: FORMER OWNER: PFIZER PRODUCTS INC.

Effective date: 20091127

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20091127

Address after: New York, United States

Applicant after: Pfizer Limited

Co-applicant after: Osi Pharm Inc.

Address before: Connecticut, USA

Applicant before: Pfizer products company

Co-applicant before: Osi Pharm Inc.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1111359

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100811

Termination date: 20200802